Genotype and phenotype spectrum of NRAS germline variants

Franziska Altmüller, Christina Lissewski, Debora Bertola, Elisabetta Flex, Zornitza Stark, Stephanie Spranger, Gareth Baynam, Michelle Buscarilli, Sarah Dyack, Jane Gillis, Helger G. Yntema, Francesca Pantaleoni, Rosa L.E. Van Loon, Sara MacKay, Kym Mina, Ina Schanze, Tiong Yang Tan, Maie Walsh, Susan M. White, Marena R. Niewisch & 6 others Sixto García-Miñaúr, Diego Plaza, Mohammad Reza Ahmadian, Hélène Cavé, Marco Tartaglia, Martin Zenker

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

RASopathies comprise a group of disorders clinically characterized by short stature, heart defects, facial dysmorphism, and varying degrees of intellectual disability and cancer predisposition. They are caused by germline variants in genes encoding key components or modulators of the highly conserved RAS-MAPK signalling pathway that lead to dysregulation of cell signal transmission. Germline changes in the genes encoding members of the RAS subfamily of GTPases are rare and associated with variable phenotypes of the RASopathy spectrum, ranging from Costello syndrome (HRAS variants) to Noonan and Cardiofaciocutaneous syndromes (KRAS variants). A small number of RASopathy cases with disease-causing germline NRAS alterations have been reported. Affected individuals exhibited features fitting Noonan syndrome, and the observed germline variants differed from the typical oncogenic NRAS changes occurring as somatic events in tumours. Here we describe 19 new cases with RASopathy due to disease-causing variants in NRAS. Importantly, four of them harbored missense changes affecting Gly12, which was previously described to occur exclusively in cancer. The phenotype in our cohort was variable but well within the RASopathy spectrum. Further, one of the patients (c.35G>A; p.(Gly12Asp)) had a myeloproliferative disorder, and one subject (c.34G>C; p.(Gly12Arg)) exhibited an uncharacterized brain tumour. With this report, we expand the genotype and phenotype spectrum of RASopathy-associated germline NRAS variants and provide evidence that NRAS variants do not spare the cancer-associated mutation hotspots.

Original languageEnglish
Pages (from-to)823-831
Number of pages9
JournalEuropean Journal of Human Genetics
Volume25
Issue number7
DOIs
Publication statusPublished - Jun 1 2017

Fingerprint

Genotype
Noonan Syndrome
Phenotype
Neoplasms
Costello Syndrome
Myeloproliferative Disorders
GTP Phosphohydrolases
Brain Neoplasms
Intellectual Disability
Genes
Mutation

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Altmüller, F., Lissewski, C., Bertola, D., Flex, E., Stark, Z., Spranger, S., ... Zenker, M. (2017). Genotype and phenotype spectrum of NRAS germline variants. European Journal of Human Genetics, 25(7), 823-831. https://doi.org/10.1038/ejhg.2017.65

Genotype and phenotype spectrum of NRAS germline variants. / Altmüller, Franziska; Lissewski, Christina; Bertola, Debora; Flex, Elisabetta; Stark, Zornitza; Spranger, Stephanie; Baynam, Gareth; Buscarilli, Michelle; Dyack, Sarah; Gillis, Jane; Yntema, Helger G.; Pantaleoni, Francesca; Van Loon, Rosa L.E.; MacKay, Sara; Mina, Kym; Schanze, Ina; Tan, Tiong Yang; Walsh, Maie; White, Susan M.; Niewisch, Marena R.; García-Miñaúr, Sixto; Plaza, Diego; Ahmadian, Mohammad Reza; Cavé, Hélène; Tartaglia, Marco; Zenker, Martin.

In: European Journal of Human Genetics, Vol. 25, No. 7, 01.06.2017, p. 823-831.

Research output: Contribution to journalArticle

Altmüller, F, Lissewski, C, Bertola, D, Flex, E, Stark, Z, Spranger, S, Baynam, G, Buscarilli, M, Dyack, S, Gillis, J, Yntema, HG, Pantaleoni, F, Van Loon, RLE, MacKay, S, Mina, K, Schanze, I, Tan, TY, Walsh, M, White, SM, Niewisch, MR, García-Miñaúr, S, Plaza, D, Ahmadian, MR, Cavé, H, Tartaglia, M & Zenker, M 2017, 'Genotype and phenotype spectrum of NRAS germline variants', European Journal of Human Genetics, vol. 25, no. 7, pp. 823-831. https://doi.org/10.1038/ejhg.2017.65
Altmüller F, Lissewski C, Bertola D, Flex E, Stark Z, Spranger S et al. Genotype and phenotype spectrum of NRAS germline variants. European Journal of Human Genetics. 2017 Jun 1;25(7):823-831. https://doi.org/10.1038/ejhg.2017.65
Altmüller, Franziska ; Lissewski, Christina ; Bertola, Debora ; Flex, Elisabetta ; Stark, Zornitza ; Spranger, Stephanie ; Baynam, Gareth ; Buscarilli, Michelle ; Dyack, Sarah ; Gillis, Jane ; Yntema, Helger G. ; Pantaleoni, Francesca ; Van Loon, Rosa L.E. ; MacKay, Sara ; Mina, Kym ; Schanze, Ina ; Tan, Tiong Yang ; Walsh, Maie ; White, Susan M. ; Niewisch, Marena R. ; García-Miñaúr, Sixto ; Plaza, Diego ; Ahmadian, Mohammad Reza ; Cavé, Hélène ; Tartaglia, Marco ; Zenker, Martin. / Genotype and phenotype spectrum of NRAS germline variants. In: European Journal of Human Genetics. 2017 ; Vol. 25, No. 7. pp. 823-831.
@article{0a31ba4a1a9a4f3882e1874bf7e1a5b0,
title = "Genotype and phenotype spectrum of NRAS germline variants",
abstract = "RASopathies comprise a group of disorders clinically characterized by short stature, heart defects, facial dysmorphism, and varying degrees of intellectual disability and cancer predisposition. They are caused by germline variants in genes encoding key components or modulators of the highly conserved RAS-MAPK signalling pathway that lead to dysregulation of cell signal transmission. Germline changes in the genes encoding members of the RAS subfamily of GTPases are rare and associated with variable phenotypes of the RASopathy spectrum, ranging from Costello syndrome (HRAS variants) to Noonan and Cardiofaciocutaneous syndromes (KRAS variants). A small number of RASopathy cases with disease-causing germline NRAS alterations have been reported. Affected individuals exhibited features fitting Noonan syndrome, and the observed germline variants differed from the typical oncogenic NRAS changes occurring as somatic events in tumours. Here we describe 19 new cases with RASopathy due to disease-causing variants in NRAS. Importantly, four of them harbored missense changes affecting Gly12, which was previously described to occur exclusively in cancer. The phenotype in our cohort was variable but well within the RASopathy spectrum. Further, one of the patients (c.35G>A; p.(Gly12Asp)) had a myeloproliferative disorder, and one subject (c.34G>C; p.(Gly12Arg)) exhibited an uncharacterized brain tumour. With this report, we expand the genotype and phenotype spectrum of RASopathy-associated germline NRAS variants and provide evidence that NRAS variants do not spare the cancer-associated mutation hotspots.",
author = "Franziska Altm{\"u}ller and Christina Lissewski and Debora Bertola and Elisabetta Flex and Zornitza Stark and Stephanie Spranger and Gareth Baynam and Michelle Buscarilli and Sarah Dyack and Jane Gillis and Yntema, {Helger G.} and Francesca Pantaleoni and {Van Loon}, {Rosa L.E.} and Sara MacKay and Kym Mina and Ina Schanze and Tan, {Tiong Yang} and Maie Walsh and White, {Susan M.} and Niewisch, {Marena R.} and Sixto Garc{\'i}a-Mi{\~n}a{\'u}r and Diego Plaza and Ahmadian, {Mohammad Reza} and H{\'e}l{\`e}ne Cav{\'e} and Marco Tartaglia and Martin Zenker",
year = "2017",
month = "6",
day = "1",
doi = "10.1038/ejhg.2017.65",
language = "English",
volume = "25",
pages = "823--831",
journal = "European Journal of Human Genetics",
issn = "1018-4813",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Genotype and phenotype spectrum of NRAS germline variants

AU - Altmüller, Franziska

AU - Lissewski, Christina

AU - Bertola, Debora

AU - Flex, Elisabetta

AU - Stark, Zornitza

AU - Spranger, Stephanie

AU - Baynam, Gareth

AU - Buscarilli, Michelle

AU - Dyack, Sarah

AU - Gillis, Jane

AU - Yntema, Helger G.

AU - Pantaleoni, Francesca

AU - Van Loon, Rosa L.E.

AU - MacKay, Sara

AU - Mina, Kym

AU - Schanze, Ina

AU - Tan, Tiong Yang

AU - Walsh, Maie

AU - White, Susan M.

AU - Niewisch, Marena R.

AU - García-Miñaúr, Sixto

AU - Plaza, Diego

AU - Ahmadian, Mohammad Reza

AU - Cavé, Hélène

AU - Tartaglia, Marco

AU - Zenker, Martin

PY - 2017/6/1

Y1 - 2017/6/1

N2 - RASopathies comprise a group of disorders clinically characterized by short stature, heart defects, facial dysmorphism, and varying degrees of intellectual disability and cancer predisposition. They are caused by germline variants in genes encoding key components or modulators of the highly conserved RAS-MAPK signalling pathway that lead to dysregulation of cell signal transmission. Germline changes in the genes encoding members of the RAS subfamily of GTPases are rare and associated with variable phenotypes of the RASopathy spectrum, ranging from Costello syndrome (HRAS variants) to Noonan and Cardiofaciocutaneous syndromes (KRAS variants). A small number of RASopathy cases with disease-causing germline NRAS alterations have been reported. Affected individuals exhibited features fitting Noonan syndrome, and the observed germline variants differed from the typical oncogenic NRAS changes occurring as somatic events in tumours. Here we describe 19 new cases with RASopathy due to disease-causing variants in NRAS. Importantly, four of them harbored missense changes affecting Gly12, which was previously described to occur exclusively in cancer. The phenotype in our cohort was variable but well within the RASopathy spectrum. Further, one of the patients (c.35G>A; p.(Gly12Asp)) had a myeloproliferative disorder, and one subject (c.34G>C; p.(Gly12Arg)) exhibited an uncharacterized brain tumour. With this report, we expand the genotype and phenotype spectrum of RASopathy-associated germline NRAS variants and provide evidence that NRAS variants do not spare the cancer-associated mutation hotspots.

AB - RASopathies comprise a group of disorders clinically characterized by short stature, heart defects, facial dysmorphism, and varying degrees of intellectual disability and cancer predisposition. They are caused by germline variants in genes encoding key components or modulators of the highly conserved RAS-MAPK signalling pathway that lead to dysregulation of cell signal transmission. Germline changes in the genes encoding members of the RAS subfamily of GTPases are rare and associated with variable phenotypes of the RASopathy spectrum, ranging from Costello syndrome (HRAS variants) to Noonan and Cardiofaciocutaneous syndromes (KRAS variants). A small number of RASopathy cases with disease-causing germline NRAS alterations have been reported. Affected individuals exhibited features fitting Noonan syndrome, and the observed germline variants differed from the typical oncogenic NRAS changes occurring as somatic events in tumours. Here we describe 19 new cases with RASopathy due to disease-causing variants in NRAS. Importantly, four of them harbored missense changes affecting Gly12, which was previously described to occur exclusively in cancer. The phenotype in our cohort was variable but well within the RASopathy spectrum. Further, one of the patients (c.35G>A; p.(Gly12Asp)) had a myeloproliferative disorder, and one subject (c.34G>C; p.(Gly12Arg)) exhibited an uncharacterized brain tumour. With this report, we expand the genotype and phenotype spectrum of RASopathy-associated germline NRAS variants and provide evidence that NRAS variants do not spare the cancer-associated mutation hotspots.

UR - http://www.scopus.com/inward/record.url?scp=85020448048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020448048&partnerID=8YFLogxK

U2 - 10.1038/ejhg.2017.65

DO - 10.1038/ejhg.2017.65

M3 - Article

VL - 25

SP - 823

EP - 831

JO - European Journal of Human Genetics

JF - European Journal of Human Genetics

SN - 1018-4813

IS - 7

ER -